The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Design and Conduct Considerations for First‐in‐Human Trials
Open accessAbstract
A milestone step in translational science to transform basic scientific discoveries into therapeutic applications is the advancement of a drug candidate from preclinical studies to initial human testing. First‐in‐human (FIH) trials serve as the link to advance new promising drug candidates and are conducted primarily to determine the safe dose range for further clinical development. Cross‐functional collaboration is essential to ensure efficient and successful FIH trials. The aim of this publication is to serve as a tutorial for conducting FIH trials for both small molecule and biological drug candidates with topics covering regulatory requirements, preclinical safety testing, study design considerations, safety monitoring, biomarker assessment, and global considerations. An emphasis is placed on FIH trial design considerations, including starting dose selection, study size and population, dose escalation scheme, and implementation of adaptive designs. In light of the recent revision of the European Medicines Agency (EMA) guideline on FIH trials to promote safety and mitigate risk, we also discuss new measures introduced in the guideline that impact FIH trial design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648 · cited 1×
“The allometric approach is a less complicated empirical approach developed based on the cross species similarities in biology, physiology, and anatomy utilizing a power function correlating physiological parameters with body size.(19)”
MethodControversy in Counting and Attributing Events in Clinical Trials
Sackett, D. L., & Gent, M. (1979) · New England Journal of Medicine · doi:10.1056/nejm197912273012602 · Cited by 413
Interspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257
Translation of Innovative Designs Into Phase I Trials
Rogatko, A., Schoeneck, D., Jonas, W., Tighiouart, M., Khuri, F. R., & Porter, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1012 · Cited by 217
Fixed Dosing Versus Body Size—Based Dosing of Monoclonal Antibodies in Adult Clinical Trials
Wang, D. D., Zhang, S., Zhao, H., Men, A. Y., & Parivar, K. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337512 · Cited by 192
van Gerven, J., & Bonelli, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13550 · Cited by 162
Huh, Y., Smith, D. E., & Rose Feng, M. (2011) · Xenobiotica · doi:10.3109/00498254.2011.598582 · Cited by 98
Nagilla, R., & Ward, K. W. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20169 · Cited by 96
Lang, T. A., White, N. J., Hien, T. T., Farrar, J. J., Day, N. P. J., Fitzpatrick, R., Angus, B. J., Denis, E., Merson, L., Cheah, P. Y., et al. (2010) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000619 · Cited by 78
Cited by
Gasiorek, A., Heydorn, A., Gabery, S., Hjerpsted, J. B., Kirkeby, K., Kruse, T., Petersen, S. B., Toubro, S., Vegge, A., & Key, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01176-6 · Cited by 46
Metadata
- Authors
- Shen, J., Swift, B., Mamelok, R., Pine, S., Sinclair, J., & Attar, M.
- Venue
- Clinical and Translational Science
- Publisher
- Wiley
- Published
- 2018-08-24
- Volume
- 12
- Issue
- 1
- Pages
- 6-19
- ISSN
- 1752-8054 (ISSN-L)
- 1752-8062
- OpenAlex
- W2884281315
- Cited by
- 176
- References
- 9
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.